Iguratimod | 艾拉莫德 | MedChemExpress (MCE)

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Iguratimod

CAS No. : 123663-49-0

MCE 国际站：Iguratimod

产品活性：Iguratimod 是一种抗风湿剂，能够有效地抑制 COX-2 的活性，IC₅₀ 值为 20 μM (7.7 μg/mL)，而对 COX-1 无作用；Iguratimod 同时为巨噬细胞移动抑制因子 (MIF) 抑制剂，IC₅₀ 值为 6.81 μM。

研究领域：Immunology/Inflammation

作用靶点：Macrophage migration inhibitory factor (MIF)  |  COX

In Vitro: Iguratimod (T-614) is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC₅₀ of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod (0.1, 1, 10 μg/mL) inhibits bradykinin-stimulated PGE2 release from fibroblasts. Iguratimod suppresses the COX activity from bradykinin stimulated fibroblasts in a concentration-dependent manner, with an IC₅₀ of 48 μg/mL. Iguratimod (10 and 30 μg/mL) also dose-dependently inhibits COX-2 mRNA levels. In addition, Iguratimod potently inhibits macrophage migration inhibitory factor (MIF) with an IC₅₀ of 6.81 μM. Iguratimod is synergetic with glucocorticoids in vitro.

In Vivo: Iguratimod (5 or 20 mg/kg) shows analgesic effect, significantly improves the pain withdrawal threshold of the left hind paw in dose-dependent manner in rats. Iguratimod (5 or 20 mg/kg) reduces the elevation of pERK1/2 and c-Fos in the spinal cord induced by cancer cell inoculation. Iguratimod also dose-dependently decreases the IL-6 levels in rats. In Iguratimod-treated rats, the activity of osteoclasts is weaker than the control group. Iguratimod (20 mg/kg i.p.) shows significantly increased survival in BALB/c mice that are vulnerable to endotoxemia, and attenuates TNFα release measured in serum isolated 90 min post-LPS administration in wild-type C57BL/6 mice.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Pyroptosis Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Pancreatic Cancer Compound Library  |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Antidepressant Compound Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Macrophage Related Compound Library  |  Multi-Target Compound Library  |  Radioprotector Library  |  Acetaminophen  |  Indomethacin  |  EIPA  |  Celecoxib  |  Aspirin  |  Oxidopamine hydrobromide  |  Deferiprone  |  Diclofenac  |  ISO-1  |  Gallic acid  |  Ibuprofen  |  Catechin  |  20(S)-Ginsenoside Rg3  |  Cucurbitacin B  |  Meloxicam  |  Carprofen  |  4-IPP  |  (-)-Epicatechin  |  NS-398  |  Naproxen  |  Xanthohumol  |  Flufenamic acid  |  Salicylic acid  |  Phenacetin  |  Ketoprofen  |  Hederagenin

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。